The report supports previous clinical trials that found the GLP-1 receptor agonist drug semaglutide reduced kidney disease progression in patients with Type 2 diabetes.
The study, a randomized and controlled clinical trial, tested the effectiveness of montelukast in 1,250 outpatients with acute post-COVID-19 symptoms.
Despite the well-established link between high salt intake and cardiovascular disease and stroke, the mechanism of SSBP is poorly understood, and it remains an untreatable cardiovascular risk with no widely available diagnostic tool.
The seventh annual event invites students to conduct science experiments, join in hands-on activities, and win prizes and giveaways.
The event brings physician-scientists, resident physicians, MD, MD/PhD and undergraduate students together to promote mentorship, provide information and showcase student research.
Nobel laureate Venki Ramakrishnan, PhD, center, author of Why We Die: The New Science of Aging and the Quest for Immortality, delivered the Sept. 26 Discovery Lecture.